Additional trials published between February and June 2020 that affected the guideline recommendations were also included. For specific search terms used, please see the Data Sup- plement, which also contains the final evidence tables that summarize the evidence used by the guideline writ- ing group to formulate recommendations. References selected and published in the present document are representative and not all inclusive. An independent Evidence Review Committee was commissioned to perform a formal systematic review of a critical clinical question (Table 1) related to secondary stroke prevention, the results of which were considered by the writing group for incorporation into the present guideline. Concurrently with this process, writing group members evaluated study data relevant to the rest of the guideline. The results of these evidence reviews were evaluated by the writing group for incorporation into the present guideline. Each topic area was assigned a primary author and a primary, and sometimes secondary, reviewer. Author assignments were based on the areas of expertise of the members of the writing group members and their lack of any relationships with industry related to the sec- tion material. All recommendations were fully reviewed and discussed among the full committee to allow diverse perspectives and considerations for this guideline. Rec- ommendations were then voted on to reach consensus. The systematic review has been published in conjunc- tion with this guideline and includes its respective data 1.2. Organization of the Writing Group The writing group consisted of neurologists, neurological surgeons, cardiologists, internists, and a lay/patient rep- resentative. The writing group included representatives from the AHA/ASA and the American Academy of Neu- rology. Appendix 1 lists writing group members relevant relationships with industry and other entities. For the pur- poses of full transparency, the writing group members comprehensive disclosure information is available online. 1.3. 